Lixin Lang

发表

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

M. Kudo, A. El-Khoueiry, B. Sangro, 2017, The Lancet.

Phase I/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209-040.

T. Yau, B. Sangro, T. Crocenzi, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety and antitumor activity of nivolumab (nivo) in patients (pts) with advanced hepatocellular carcinoma (HCC): Interim analysis of dose-expansion cohorts from the phase 1/2 CheckMate-040 study.

M. Kudo, A. El-Khoueiry, B. Sangro, 2016 .

Phase I/II safety and antitumor activity of nivolumab (nivo) in patients (pts) with advanced hepatocellular carcinoma (HCC): Interim analysis of the CheckMate-040 dose escalation study.

A. El-Khoueiry, B. Sangro, T. Yau, 2016 .

A randomized, multicenter, phase 3 study of nivolumab vs sorafenib as first-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): CheckMate-459.

B. Sangro, Jeffrey Anderson, C. D. Cruz, 2016 .

Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors

J. Lunceford, R. Cristescu, A. Albright, 2022, Journal for ImmunoTherapy of Cancer.

Evaluation of the TruSight Oncology 500 Assay for Routine Clinical Testing of Tumor Mutational Burden and Clinical Utility for Predicting Response to Pembrolizumab.

M. Kibukawa, R. Cristescu, Lixin Lang, 2022, The Journal of molecular diagnostics : JMD.

A first-in-human, phase I study of an oral hedgehog (HH) pathway antagonist, BMS-833923 (XL139), in subjects with advanced or metastatic solid tumors.

Lixin Lang, S. Alberts, K. Papadopoulos, 2010 .

Predictive probability methods for interim monitoring in clinical trials with longitudinal outcomes

Lixin Lang, Kay Tatsuoka, Qi Tang, 2018, Statistics in medicine.

Nivolumab (nivo) in sorafenib (sor)-naive and -experienced pts with advanced hepatocellular carcinoma (HCC): CheckMate 040 study.

M. Kudo, T. Yau, A. El-Khoueiry, 2017 .

Nivolumab in sorafenib-experienced patients with advanced hepatocellular carcinoma (HCC) with or without chronic viral hepatitis: CheckMate 040 study

M. Kudo, A. El-Khoueiry, B. Sangro, 2017 .

Abstract A55: A first‐in‐human, phase I study of an oral hedgehog pathway antagonist, BMS‐833923 (XL139), in subjects with advanced or metastatic solid tumors

A. Tolcher, Lixin Lang, S. Alberts, 2009 .

A Phase I Study of An Oral Hedgehog Pathway Antagonist, BMS-833923, in Patients with Relapsed or Refractory Multiple Myeloma,

C. Huff, Lixin Lang, L. Camacho, 2011 .

Practical statistical considerations for investigating anti-tumor treatments in mice

Lixin Lang, David Gold, Kim E. Zerba, 2018, Journal of Applied Statistics.